MTOR and breast neoplasm: While pathways such as PI3K/AKT/MTOR are known to be activated across the majority of breast tumours22, our analysis shows that other complementary tumorigenesis-related pathways including RAS/MAPK are also activated in a small set of breast tumours due to specific genomic or proteomic alterations, representing alternative treatment opportunities.